As Ei­sai, Bio­gen plot a course to ac­cel­er­at­ed ap­provals for Alzheimer’s drug, a mob of skep­tics are wait­ing to ...

7 years ago
R&D
Pharma

Mar­ket slack­er Cel­gene does some­thing good for a change, look­ing to turn the cor­ner on past mishaps

7 years ago
R&D

Il­lu­mi­na's found­ing sci­en­tist launch­es soft­ware start­up to track fast-mu­tat­ing hos­pi­tal bugs

7 years ago
People
Startups

GSK banks on promis­ing da­ta from its PhI­II Gem­i­ni pro­gram to stare down Gilead on HIV — but there are plen­ty of ...

7 years ago
R&D

Top 10 pipeline blowups, set­backs and sna­fus in H1 2018

7 years ago
R&D
Special

Pfiz­er/Mer­ck KGaA launch sol­id tu­mor com­bo study with Leap; As­traZeneca and Im­munomedics to test ADC can­cer com­bo

7 years ago
News Briefing

GSK gains a PRV along­side FDA ap­proval for re­cur­ring malar­ia treat­ment

7 years ago
Pharma

FDA pos­es some tough ques­tions for GSK’s pitch to gain an ap­proval for Nu­cala in COPD

7 years ago
Pharma

Lil­ly inks R&D deal with An­i­ma, pay­ing $44M in re­search fund­ing and up­front pay­ments

7 years ago
R&D
Pharma

Fa­heem Has­nain ups cash haul to $330M for a fledg­ling biotech that is mov­ing ‘at light speed’

7 years ago
Financing

Sang­amo puts down $84M to ac­quire Tx­Cell, div­ing in­to CAR-Treg space, au­toim­mune dis­eases

7 years ago
Deals

Hu­man Longevi­ty blasts Craig Ven­ter, claim­ing he was fired, then stole trade se­crets — poach­ing staffers for ri­val ...

7 years ago
People

Num­ber 7? Cel­gene part­ner BeiGene joins the crowd with stel­lar PD-1/L1 da­ta from a piv­otal test

7 years ago
R&D

Fed­er­al judges ban Al­ler­gan’s sov­er­eign im­mu­ni­ty scheme in a slap­down that will bol­ster in­ter partes re­view for ...

7 years ago
Bioregnum
Opinion

Agios scores its sec­ond new drug ap­proval, ivosi­denib heads to the AML mar­ket

7 years ago
Pharma

An­tho­ny Quinn ce­ments Ae­glea CEO spot; Hu­man Longevi­ty bumps David Karow up to the top

7 years ago
Peer Review

BMS part­ners with Grit­stone on sol­id tu­mor com­bos; Roche's Alzheimer's di­ag­nos­tic gets break­through sta­tus

7 years ago
News Briefing

Bat­tered and weary, Vi­cal flags for help fol­low­ing its line­up of lemons

7 years ago
R&D

So­bi signs $450M deal for rare dis­ease drug ema­palum­ab, boost­ing its in­flam­ma­tion, I/O pipeline

7 years ago
Pharma

Roche has tak­en the Trump pledge, join­ing Pfiz­er, No­var­tis and Mer­ck in promis­ing to hold the line on drug prices

7 years ago
Pharma

This week’s Nas­daq casi­no win­nings: About $700M for 6 biotech IPOs as shares start mov­ing north

7 years ago
Financing

PureTech grabs up to $36M from Roche to re­search milk-in­spired de­liv­ery plat­form

7 years ago
Pharma

Nab­bing late-stage drug, PTC ac­quires gene ther­a­py start­up Ag­ilis for $200M in cash/stock

7 years ago
Deals

In an­oth­er win for Trump, Mer­ck takes the drug pric­ing pledge. Its cuts are a joke, but is this an in­dus­try tip­ping ...

7 years ago
Pharma
First page Previous page 1010101110121013101410151016 Next page Last page
A service from the Financial Times